埃克替尼对血脂含量的影响:一项单中心回顾性研究  

Effect of icotinib on human blood lipid contents: a single center retrospective study

作　　者：陈玉冰 于京京 曾永联 袁观斗 曾智明[4] 何松青[1,2,3] Chen Yubing;Yu Jingjing;Zeng Yonglian;Yuan Guandou;Zeng Zhiming;He Songqing(Department of Hepatobiliary Surgery,First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China;Key Laboratory of Early Prevention and Treatment of Regional High Incidence Tumors in Zone 2,Ministry of Education(Guangxi Medical University),Nanning 530021,China;Key Laboratory of Immunology and Metabolism Research on Liver Diseases in Guangxi,Nanning 530021,China;Department of Oncology,First Affiliated Hospital of Western Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院肝胆外科,南宁530021 [2]区域性高发肿瘤早期防治研究教育部重点实验室(广西医科大学),南宁530021 [3]广西肝脏疾病免疫与代谢研究重点实验室,南宁530021 [4]广西医科大学第一附属医院肿瘤科,南宁530021

出　　处：《中华实验外科杂志》2024年第8期1691-1695,共5页Chinese Journal of Experimental Surgery

基　　金：广西科技基地和人才专项(桂科AA21220002);国家重点研发计划项目(2022YFE0131600);广西医科大学高水平创新团队及杏湖学者计划;111计划(D17011)。

摘　　要：目的探究酪氨酸激酶抑制剂埃克替尼对临床患者血脂的影响。方法通过回顾性分析方法收集2015年1月至2019年7月期间,于广西医科大学第一附属医院接受埃克替尼治疗的符合纳入标准且随访信息完整的36例晚期肺癌患者病历信息,将其分为4组。观察埃克替尼治疗前后血脂水平的变化。应用配对样本t检验、方差分析、卡方检验进行数据分析。结果埃克替尼治疗至少1个月(中位治疗时间[1个月,6个月])可显著降低患者血清总胆固醇(治疗前均值4.886 mmol/L,治疗后均值4.409 mmol/L,t=2.787,P<0.01)、低密度脂蛋白(治疗前均值2.957 mmol/L,治疗后均值2.53 mmol/L,t=9.596,P<0.01)和载脂蛋白B(治疗前均值1.003 mmol/L,治疗后均值0.900 mmol/L,t=2.828,P<0.01)的含量。结论埃克替尼可有效降低肺癌患者血脂含量,提示其可能用于非酒精性脂肪性肝病的降脂治疗。Objective To explore the effect of tyrosine kinase inhibitors(TKIs)that can bind to epidermal growth factor receptor(EGFR)on blood lipid in patients.MethodsIn this study,we retrospectively reviewed medical record for patients with advanced lung cancer and treated with Icotinib,a first generation of EGFR-TKI,from January 2015 to July 2019.A total of 36 patients who had complete follow-up medical information were recruited and divided into four groups.The changes in blood lipid levels before and after treatment were evaluated.The paired sample Student’s t test,analysis of variance(ANOVA)with Bonferroni post hoc test and Chi Square test were performed for data analysis.ResultsIcotinib could significantly reduce the content of serum total cholesterol(the mean before treatment was 4.886 mmol/L,the mean after treatment was 4.409 mmol/L,t=2.787,P<0.01),low density lipoprotein(the mean before treatment was 2.957 mmol/L,the mean after treatment was 2.53 mmol/L,t=9.596,P<0.01)and Apolipoprotein B(the mean before treatment was 1.003 mmol/L,the mean after treatment was 0.900 mmol/L,t=2.828,P<0.01)after treatment with Icotinib for at least one month[duration of treatment],IQR(one month,6 months).ConclusionIcotinib can effectively reduce the lipid content of patients,suggesting that it may be used in the treatment of non-alcoholic fatty liver disease.

关 键 词：表皮生长因子受体抑制剂 埃克替尼 高脂血症 高胆固醇血症 回顾性研究 

分 类 号：R734.2[医药卫生—肿瘤]